According to the information on the clinical trials database maintained by the U...
Johnson & Johnson developed seltorexant as an orexin-2 antagonist to prevent exc...
In a bid to venture into the healthcare field from its domain in the industrial ...
Gerresheimer, the maker of innovative systems and solutions and a partner to the...
Daiichi Sankyo and AstraZeneca have applied to the FDA for their second-generati...
Neuren Pharmaceuticals revealed key outcomes from its Phase 2 study of NNZ-2591 ...
Biogen is investing $1.15 billion in Chris Viehbacher’s strategy to diversify th...
Novo Nordisk aims to be the first to launch a weekly insulin product, particular...
The recently published study in the New England Journal of Medicine, as well as ...
Swedish pharma company Vicore announced the results of its phase 2a AIR trial fo...
AstraZeneca is reportedly planning to build a $1.5 billion facility in Singapore...
In a phase 2 study on idiopathic pulmonary fibrosis (IPF), Endeavor BioMedicines...
Results from two clinical trials showed that a once-weekly version of insulin de...
After the disappointing outcome of early-stage trials for their antisense drug B...
Recently, the U.S. Food and Drug Administration (FDA) approved Imdelltra, a new ...
The rapidly developing area of pulsed field ablation is gaining momentum all ove...
